Our prior work in numerous prostate cancer models revealed the two kinases to have a synthetic lethal relationship—such that genetic ablation or pharmacologic inhibition of CDK13 preferentially impairs tumor cell survival in the setting of CDK12 inactivation (5). Here, CDK13 is linked to Familial prostate cancer.